John Overdeck’s Dr. Reddy's Laboratories RDY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-21,800
Closed -$302K 5360
2026
Q1
$302K Buy
+21,800
New +$303K ﹤0.01% 4068
2024
Q2
Sell
-48,255
Closed -$708K 3274
2024
Q1
$708K Sell
48,255
-205,555
-81% -$3M ﹤0.01% 2162
2023
Q4
$3.53M Sell
253,810
-426,020
-63% -$5.7M 0.01% 1178
2023
Q3
$9.09M Sell
679,830
-186,450
-22% -$2.52M 0.02% 640
2023
Q2
$10.9M Buy
866,280
+319,570
+58% +$3.73M 0.03% 603
2023
Q1
$6.22M Buy
546,710
+456,710
+507% +$4.93M 0.02% 803
2022
Q4
$932K Buy
90,000
+62,500
+227% +$674K ﹤0.01% 1725
2022
Q3
$288K Sell
27,500
-90,155
-77% -$960K ﹤0.01% 1984
2022
Q2
$1.3M Sell
117,655
-47,895
-29% -$521K ﹤0.01% 1417
2022
Q1
$1.84M Buy
+165,550
New +$1.88M 0.01% 1385
2020
Q3
Sell
-301,710
Closed -$3.2M 3477
2020
Q2
$3.2M Buy
+301,710
New +$3.07M 0.02% 866
2018
Q3
Sell
-1,372,810
Closed -$8.84M 3511
2018
Q2
$8.84M Buy
+1,372,810
New +$8.66M 0.03% 717
2016
Q1
Sell
-428,395
Closed -$3.97M 3072
2015
Q4
$3.97M Buy
+428,395
New +$4.69M 0.02% 759

Other funds holding RDY

John Overdeck's RDY Position: Q2 2026 in Review

John Overdeck sold out of Dr. Reddy's Laboratories (RDY) in Q2 2026, closing a stake of 21,800 shares — an estimated $302K sold.

John Overdeck first reported a position in RDY in Q4 2015 and held it in 13 quarters. The position peaked at $10.9M in Q2 2023. 238 funds tracked by Wall St. Rank hold RDY as of Q2 2026.

  • John Overdeck reported no remaining Dr. Reddy's Laboratories position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 21,800 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $302K.
  • John Overdeck first reported a position in Dr. Reddy's Laboratories in Q4 2015 and held it in 13 quarters.
  • John Overdeck's Dr. Reddy's Laboratories position peaked at $10.9M in Q2 2023.
  • 238 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.